Management of rabies in humans

Clinical Infectious Diseases

Volumn 36, Issue 1, 2003, Pages 60-63

  Jackson, Alan C ^a,i   Warrell, Mary J ^b   Rupprecht, Charles E ^c   Ertl, Hildegund C J ^j   Dietzschold, Bernhard ^e   O'Reilly, Michael ^c   Leach, Richard P ^f   Fu, Zhen F ^d   Wunner, William H ^j   Bleck, Thomas P ^g   Wilde, Henry ^h  

^a QUEEN S UNIVERSITY   (Canada)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f Glens Falls Hospital   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

^h CHULALONGKORN UNIVERSITY   (Thailand)

ⁱ KINGSTON GENERAL HOSPITAL   (Canada)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANALGESIC AGENT; ANTICONVULSIVE AGENT; CORTICOSTEROID; KETAMINE; MONOCLONAL ANTIBODY; NEUROMUSCULAR BLOCKING AGENT; NEUTRALIZING ANTIBODY; RABIES IMMUNOGLOBULIN; RABIES VACCINE; RIBAVIRIN; SEDATIVE AGENT; VIDARABINE;

ADRENAL CORTEX INSUFFICIENCY; CLINICAL FEATURE; CLINICAL RESEARCH; DECISION MAKING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; EARLY DIAGNOSIS; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RABIES; REVIEW; SURVIVAL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ADRENAL CORTEX HORMONES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON-ALPHA; KETAMINE; MICE; PALLIATIVE CARE; RABIES; RABIES VACCINES; RIBAVIRIN;

EID: 0037234902     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344905     Document Type: Review

References (39)

1. World Health Organization (WHO). World survey for rabies no. 35 for the year 1999. WHO/CDS/CSR/EPH/2002. Geneva: World Health Organization, 2002.
2. Centers for Disease Control and Prevention. Human rabies prevention - United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999; 48(RR-1):1-21.
3. Gode GR, Raju AV, Jayalakshmi TS, Kaul HL, Bhide NK. Intensive care in rabies therapy: clinical observations. Lancet 1976; 2(7975):6-8.
4. Hattwick MAW, Weis TT, Stechschulte CJ, Baer GM, Gregg MB. Recovery from rabies: a case report. Ann Intern Med 1972; 76:931-42.
5. Tillotson JR, Axelrod D, Lyman DO. Rabies in a laboratory worker - New York. MMWR Morb Mortal Wkly Rep 1977; 26:183-4.
6. Tillotson JR, Axelrod D, Lyman DO. Follow-up on rabies - New York. MMWR Morb Mortal Wkly Rep 1977; 26:249-50.
7. Porras C, Barboza JJ, Fuenzalida E, Adaros HL, Oviedo AM, Furst J. Recovery from rabies in man. Ann Intern Med 1976; 85:44-8.
8. Alvarez L, Fajardo R, Lopez E, et al. Partial recovery from rabies in a nine-year-old boy. Pediatr Infect Dis J 1994; 13:1154-5.
9. Madhusudana SN, Nagaraj D, Uday M, Ratnavalli E, Kumar MV. Partial recovery from rabies in a six-year-old girl [letter]. Int J Infect Dis 2002; 6:85-6.
10. Jackson AC. Human disease. In: Jackson AC, Wunner WH, eds. Rabies. San Diego: Academic Press, 2002:219-44.
11. Noah DL, Drenzek CL, Smith JS, et al. Epidemiology of human rabies in the United States, 1980 to 1996. Ann Intern Med 1998; 128:922-30.
12. Emmons RW, Leonard LL, DeGenaro F Jr, et al. A case of human rabies with prolonged survival. Intervirology 1973; 1:60-72.
13. Messenger SL, Smith JS, Rupprecht CE. Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States. Clin Infect Dis 2002; 35:738-47.
14. Hattwick MAW. Human rabies. Public Health Rev 1974; 3:229-74.
15. Merigan TC, Baer GM, Winkler WG, et al. Human leukocyte interferon administration to patients with symptomatic and suspected rabies. Ann Neurol 1984; 16:82-7.
16. Warrell MJ, White NJ, Looareesuwan S, et al. Failure of interferon alfa and tribavirin in rabies encephalitis. BMJ 1989; 299:830-3.
17. Dolman CL, Charlton KM. Massive necrosis of the brain in rabies. Can J Neurol Sci 1987; 14:162-5.
18. Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 2001; 285:193-9.
19. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35:1002-9.
20. World Health Organization (WHO). WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. WHO/EMC/ZOO/96.6, 1-23. Geneva: World Health Organization, 1997. Available at: http://www.who.int/emc-documents/rabies/docs/whoemczoo966.pdf. Accessed 22 November 2002.
21. Lafon M. Immunology. In: Jackson AC, Wunner WH, eds. Rabies. San Diego: Academic Press, 2002:351-69.
22. Miller DW. Immunobiology of the blood-brain barrier. J Neurovirol 1999; 5:570-8.
23. Dietzschold B, Kao M, Zheng YM, et al. Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci USA 1992; 89:7252-6.
24. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6:1375-9.
25. Tam RC, Lau JY, Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 2001; 12:261-72.
26. Bussereau F, Chermann JC, De Clercq E, Hannoun C. Search for compounds which have an inhibitory effect on rhabdovirus multiplication in vitro. Ann Virol (Inst Pasteur) 1983; 134E:127-34.
27. Bussereau F, Ermine A. Effects of heteropolyanions and nucleoside analogues on rabies virus: in vitro study of syntheses and viral production. Ann Virol (Inst Pasteur) 1983; 134E:487-506.
28. Bussereau F, Picard M, Blancou J, Sureau P. Treatment of rabies in mice and foxes with antiviral compounds. Acta Virol 1988; 32:33-49.
29. Ferrara EA, Oishi JS, Wannemacher RW Jr, Stephen EL. Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob Agents Chemother 1981; 19:1042-9.
30. Crumpacker C, Bubley G, Lucey D, Hussey S, Connor J. Ribavirin enters cerebrospinal fluid [letter]. Lancet 1986; 2(8497):45-6.
31. Brassard DL, Grace MJ, Bordens RW. Interferon-alfa as an immunotherapeutic protein. J Leukoc Biol 2002; 71:565-81.
32. Despres P, Griffin JW, Griffin DE. Antiviral activity of alfa interferon in Sindbis virus-infected cells is restored by anti-E2 monoclonal antibody treatment. J Virol 1995; 69:7345-8.
33. Weinmann E, Majer M, Hilfenhaus J. Intramuscular and/or intralumbar postexposure treatment of rabies virus-infected cynomolgus monkeys with human interferon. Infect Immun 1979; 24:24-31.
34. Reves JG, Glass PSA, Lubarsky DA. Phencyclidines (ketamine). In: Miller RD, ed. Anesthesia, 5th ed. New York: Churchill Livingstone, 2000:241-6.
35. Lockhart BP, Tordo N, Tsiang H. Inhibition of rabies virus transcription in rat cortical neurons with the dissociative anesthetic ketamine. Antimicrob Agents Chemother 1992; 36:1750-5.
36. Lockhart BP, Tsiang H, Ceccaldi PE, Guillemer S. Ketamine-mediated inhibition of rabies virus infection in vitro and in rat brain. Antivir Chem Chemother 1991; 2:9-15.
37. Gosztonyi G, Ludwig H. Interactions of viral proteins with neurotransmitter receptors may protect or destroy neurons. Curr Top Microbiol Immunol 2001; 253:121-44.
38. Enright JB, Franti CE, Frye FL, Behymer DE. The effects of corticosteroids on rabies in mice. Can J Microbiol 1970; 16:667-75.
39. Basgoz N, Frosch MP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-1998. A 32-year-old woman with pharyngeal spasms and paresthesias after a dog bite. N Engl J Med 1998; 339:105-12.